Review

The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management

Figure 1. Personalized risk assessment and lipid management in the 2026 ACC/AHA guideline.
Open the figure at full size
Figure 1. Personalized risk assessment and lipid management in the 2026 ACC/AHA guideline.Personalized risk assessment and lipid management in the 2026 ACC/AHA guideline.Sabouret et al. · CC BY

Life

Abstract

The 2026 ACC/AHA Multisociety Guideline marks a major shift in dyslipidemia management, extending the traditional LDL-C-centered approach to include non-HDL-C, ApoB, lipoprotein(a), triglyceride-rich lipoproteins, inherited lipid disorders, and severe hypertriglyceridemia.

The paper

Sorbonne Université · University of Messina

Life · 3 Sep 2026 · CC BY

doi.org/10.3390/life16091470PubMed 42795336

More on Lipid and ceramide metabolism